CTOs on the Move

LTC Group

www.ltcgroup.com

 
LTC Group is a Irving, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Interlace Medical

Interlace Medical, Inc. is a Framingham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gadsden Regional Medical Center

Gadsden Regional Medical Center is a Gadsden, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Persante Health Care

Persante Health Care is a national provider of sleep and balance center management services to hospitals, physician practices and patients. Persante`s expertise in sleep and balance related disorders dates back almost 20 years under the names of Sleep Care Centers, Sleep Tech, Mid-Atlantic School of Sleep Medicine and Blackwood Medical. The merging of these four unique industry leaders revolutionized the out-sourced delivery model of sleep and balance diagnosis and therapeutic treatment. This comprehensive approach to serving our client`s patients in a high quality manner has earned recognition and accreditation from The American Academy of Sleep Medicine and The National Sleep Foundation.

Telecare Corporation

Since 1965, Telecare has been committed to making a difference in the lives of people with serious mental illness. We believe in Recovery, and in the human ability and desire to reach its full potential. We have created an environment that puts the

Xenon Pharmateuticals

Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.